Scarica l'app Stockscreener
566.90
0.49%
3.0374
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$563.86
Aprire:
$569.02
Volume 24 ore:
546.62K
Relative Volume:
0.54
Capitalizzazione di mercato:
$59.07B
Reddito:
$14.21B
Utile/perdita netta:
$4.46B
Rapporto P/E:
14.28
EPS:
39.6877
Flusso di cassa netto:
$3.56B
1 W Prestazione:
-5.57%
1M Prestazione:
+1.81%
6M Prestazione:
-1.75%
1 anno Prestazione:
-44.02%
Intervallo 1D:
$563.51
$574.72
Intervallo di 1 settimana:
$560.97
$618.01
Portata 52W:
$476.49
$1,024.36
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
567.10 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.79 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.41 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
803.40 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
335.35 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients - Benzinga
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’ - Stocktwits
Regeneron, needing a turnaround, gains new use for cancer drug - BioPharma Dive
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo - The Globe and Mail
Will Regeneron Pharmaceuticals Inc. continue its uptrend2025 Sector Review & Community Shared Stock Ideas - newser.com
Regeneron Pharmaceuticals Inc. stock daily chart insights2025 Year in Review & Real-Time Volume Analysis Alerts - newser.com
8,976 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Bar Harbor Wealth Management - MarketBeat
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery - Yahoo
Bispecific Antibodies MarketGlobal Forecast 2025-2032, Profiles of Key PlayersF. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab - GlobeNewswire
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by QRG Capital Management Inc. - MarketBeat
Regeneron Pharmaceuticals (REGN) Stock: Dips Despite FDA’s Breakthrough Approval for Libtayo in High-Risk CSCC - parameter.io
US FDA expands use of Regeneron’s Libtayo as add-on treatment for skin cancer - 104.1 WIKY
Libtayo approved in the U.S. for adjuvant treatment of cutaneous squamous cell carcinoma - MarketScreener
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer - Reuters
Regeneron (REGN) Gains FDA Approval for Cancer Therapy Libtayo - GuruFocus
FDA Approves Regeneron's Libtayo for High-Risk Skin Cancer Treat - GuruFocus
FDA Approves Regeneron's (REGN) Libtayo for High-Risk Skin Cance - GuruFocus
Regeneron Pharmaceuticals Announces FDA Approval of Libtayo® as Adjuvant Treatment for High-Risk Cutaneous Squamous Cell Carcinoma - Quiver Quantitative
Regeneron stock rises after FDA approves Libtayo for high-risk skin cancer - Investing.com
68% Risk Reduction: Regeneron's Libtayo Approved as First Adjuvant Immunotherapy for CSCC - Stock Titan
Regeneron Pharma stock price target raised by RBC to $704 on Dupixent growth By Investing.com - Investing.com Nigeria
Regeneron Pharma stock price target raised by RBC to $704 on Dupixent growth - Investing.com
RBC Raises Price Target on Regeneron Pharmaceuticals to $704 From $695, Keeps Sector Perform Rating - MarketScreener
Dohj LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KLP Kapitalforvaltning AS Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Valeo Financial Advisors LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ameliora Wealth Management Ltd. - MarketBeat
Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Slow Capital Inc. - MarketBeat
Regeneron Pharmaceuticals to Acquire 23andMe for $256M - MSN
Galderma Punches Above Its Weight Against Dermatology Goliaths - insights.citeline.com
Regeneron Pharmaceuticals (REGN): Valuation in Focus Following Breakthrough Pipeline Results and Expanded Drug Approvals - simplywall.st
Strategies to average down on Regeneron Pharmaceuticals Inc.2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Regeneron (REGN) Projects $83 Million R&D Charge in Q3 2025 - GuruFocus
Regeneron expects $83 million IPR&D charge in third quarter 2025 results - Investing.com
Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Earnings Miss & Advanced Technical Signal Analysis - newser.com
Can trapped investors hope for a rebound in Regeneron Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Is Regeneron Pharmaceuticals Inc. stock resilient to inflationQuarterly Market Review & Verified Technical Trade Signals - newser.com
111 Capital Makes New $517,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
J. Safra Sarasin Holding AG Sells 438 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Janney Montgomery Scott LLC Has $6.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Published on: 2025-10-06 01:04:19 - newser.com
Marietta Wealth Management LLC Has $6.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why pension funds invest in Regeneron Pharmaceuticals Inc. (RGO) stock2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com
Applying Elliott Wave Theory to Regeneron Pharmaceuticals Inc.Weekly Stock Recap & Accurate Buy Signal Alerts - newser.com
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockRisk Management & Expert Approved Momentum Trade Ideas - newser.com
Why Regeneron (REGN) Is Up 6.4% After FDA Expansion and Positive Late-Stage Trial Results - simplywall.st
Mirae Asset Global Investments Co. Ltd. Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Robeco Institutional Asset Management B.V. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Financial Corp Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts - Proactive financial news
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.89%
4.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):